Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum transporter proteins involved in drug efflux are a group of membrane-bound proteins that play a central role in the development of antimalarial drug resistance. The most prominent among these is the **Plasmodium falciparum chloroquine resistance transporter** (**PfCRT**), which resides on the digestive vacuole membrane. Mutant forms of PfCRT mediate chloroquine, amodiaquine, and piperaquine resistance by actively transporting these drugs out of their site of action within the acidic digestive vacuole, thereby preventing them from inhibiting heme detoxification—a key mechanism for parasite survival during red blood cell infection. Another major player is **Plasmodium falciparum multidrug resistance protein 1** (**PfMDR1**), an ABC-type transporter also located on the digestive vacuole membrane; it modulates susceptibility to multiple antimalarials through altered expression levels or mutations affecting substrate binding and translocation. A recently characterized member is **Plasmodium falciparum Niemann-Pick type C1–related protein** (**PfNCR1**), which exports cholesterol from the parasite plasma membrane and has been identified as a novel targetable vulnerability with specific inhibitors such as MMV009108 showing direct inhibition effects. These transporters are essential not only for nutrient acquisition but also serve as primary mechanisms by which P. falciparum evades chemotherapeutic pressure—posing significant challenges for malaria control efforts worldwide. Their genetic polymorphisms serve both as biomarkers for surveillance and targets for next-generation antimalarial therapies[2][3][4][5][6].
Efflux of antimalarial drugs from the digestive vacuole or plasma membrane, reducing intracellular drug concentrations and efficacy[2][3][4][6][8] Mutations alter substrate specificity or increase activity to confer resistance[3][6]
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum chloroquine resistance transporter (PfCRT).